Market Signal Briefing

The cryptocurrency market has seen a remarkable surge in October, with Ethereum (ETH) and Solana (SOL) leading the pack among major altcoins. Both tokens have experienced over 12% gains in just the past week, drawing attention from retail and institutional investors alike.

Pi Coin trades at $0.239 after a failed bullish crossover, with bearish sentiment deepening as the token diverges from Bitcoin’s market trend.Correlation with Bitcoin fell to -0.24, signaling weak investor confidence and limited participation as momentum continues to fade.A drop toward $0.200 or $0.184 ATL is likely unless Pi reclaims $0.270 support, which could spark a short-term rebound to $0.286.Pi Coin has been trading sideways for several weeks, showing little momentum despite broader market activity. The altcoin’s consolidation phase now appears to be breaking down as market conditions deteriorate, pushing prices lower. 

Recent indicators suggest that the token could be heading toward a deeper correction if bearish sentiment persists.

Pi Coin Is Not Following BitcoinPi Coin’s correlation to Bitcoin has dropped to a negative 0.24, indicating that it is currently moving independently of the broader crypto market. This detachment is unfavorable, as Bitcoin’s recent gains have historically lifted smaller altcoins. Pi’s inability to follow this pattern highlights weakening investor confidence and diminished market participation.

Sponsored

Sponsored

This negative correlation also suggests that Pi Coin may struggle to capitalize on Bitcoin’s rally in the near term. Without a strong alignment with Bitcoin’s bullish cycle, Pi Coin risks further downside pressure as investor enthusiasm fades.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Pi Coin Correlation To Bitcoin. Source: TradingViewFrom a technical standpoint, Pi Coin’s Moving Average Convergence Divergence (MACD) indicator was on the verge of a bullish crossover last week. Such a signal typically marks the beginning of a recovery phase after an extended downtrend. 

However, worsening market conditions disrupted this momentum, delaying the reversal and extending the token’s two-week bearish streak. The failed crossover highlights the fragile state of Pi Coin’s momentum. Instead of confirming an uptrend, the indicator now suggests continued weakness. 

Pi Coin MACD. Source: TradingViewPI Price Needs To Reclaim SupportAt the time of writing, Pi Coin is trading at $0.239, just below the $0.240 threshold. The token has declined nearly 9% in the past 24 hours, reflecting growing selling pressure. Unless demand returns, Pi could continue to lose value in the coming days.

Based on current indicators, Pi Coin’s price could drop toward $0.200, with a possible retest of its all-time low (ATL) at $0.184—roughly 23% below current levels. Sustained bearish conditions would make this scenario increasingly likely.

Pi Coin Price Analysis. Source: TradingViewConversely, if the broader crypto market stabilizes, Pi Coin could stage a rebound. A move above $0.270 would invalidate the bearish outlook, paving the way for a recovery toward $0.286 and potentially higher levels.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

As part of the arrangement, Jupiter plans to “progressively convert” about $750 million of USDC from its Liquidity Provider Pool into JupUSD.

Canary cracks open the first official HBAR ETF ticker, raising approval odds to an all-time peak.

9 minutes ago

The last two times Dogecoin price rallied 300% and 445% after its monthly RSI produced a bullish cross, and the same signal has now flashed again.

138

Key takeaways:

DOGE price previously rallied 445% from an RSI bullish cross that’s again in play.

A possible breakout from an ascending triangle targets $0.65 in the days ahead.

Bullish analysts say DOGE price can reach $1 for the first time in the next few months.

Dogecoin’s (DOGE) relative strength index (RSI) produced a bullish signal in Q4 2024, a period that saw DOGE’s price rise by about 445% within a few months.

A similar DOGE price fractal is now unfolding on the charts, with a potential breakout in the coming weeks.

Past DOGE rallies saw 300% and 445% gainsThe Relative Strength Index, or RSI, is a popular momentum indicator used in technical analysis that helps traders identify the strength and direction of a trend in an asset’s price.

The indicator has produced a “bullish cross” on the monthly chart, as shown in the figure below.

Previous instances show that DOGE tends to rise sharply when the RSI line (purple) crosses above the SMA line (orange). The cryptocurrency’s gains were 302% between October 2023 and April 2024 and 445% in Q4 2024.

BTC/USD monthly chart. Source: Cointelegraph/TradingView“Whenever this signal flashes on $DOGE, pay attention,” said analyst Mikybull Crypto in an X post on Sunday, adding:

“This only indicates that a big move is imminent.”The chart above also reveals that the bullish cross of the RSI also aligns with the price retesting the 20-period simple moving average on the same time frame.

This is usually followed by a “huge bullish move,” Mikybull Crypto wrote, adding:

“$DOGE is ready to $1 from the bullish move that’s about to hit.”Will DOGE jump 160%?An ascending triangle formation on the two-day chart indicates a strengthening bullish outlook, with upside targets around $0.65, or a 161% increase from current price levels.

DOGE/USD two-day chart. Source: Cointelegraph/TradingViewAnalyst Mags is optimistic about much higher gains ahead, however, citing institutional interest from Dogecoin treasury companies and possible spot ETF approvals, which are expected in mid-October.

Dogecoin’s “God candle is incoming,” the analyst said in an X post on Tuesday.

An accompanying chart showed that DOGE’s breakout from a multimonth downtrend could see the top memecoin blast past the 2021 all-time highs above $0.73 toward $1.20.

“$DOGE to $1 + is inevitable.”DOGE/USD chart. Source: MagsAs Cointelegraph reported, multiple onchain and technical indicators also paint a picture for a DOGE price rally in Q4 2025.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.

YZi Labs, the venture investor closely affiliated with Binance co-founder Changpeng Zhao, has launched a $1 billion Builder Fund for founders and developers in the BNB Chain ecosystem amid the Binance-backed token's latest strong leg up.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Binance Coin (BNB) has been bullish in the last 30 days as the altcoin gained 49.99%, and 28.83% within the past seven days. The asset's growth trajectory suggests that BNB still has room for a further rally that could see it hit $1,500 in the ongoing bull run.

Institutional partnerships fuel BNB's utility and market confidenceAs per CryptoQuant data, an on-chain platform, Binance Coin’s rise to its current level above $1,300 is not just hype or speculative trading. Rather, BNB climbed on the back of fundamental structural and institutional changes, which are now paying off in the form of price gains.

The data analytics platform suggests that BNB’s rise is not a fluke but is supported by real demand and increased institutional adoption. Traditional finance institutions have collaborated with Binance to increase their utility and value.

Why BNB Reached $1,300

“In essence, liquidity concentration, deflationary supply mechanics, and stronger institutional ties have redefined BNB from a simple exchange token into a cornerstone asset bridging Web3 and traditional finance.” – By @xwinfinance pic.twitter.com/XKsHMMwa4M

— CryptoQuant.com (@cryptoquant_com) October 8, 2025 Notably, Franklin Templeton, the asset management firm with over $15 trillion in assets under management, has collaborated with Binance, the parent company, to develop tokenized securities. This implies that traditional assets like bonds are represented on the blockchain, a development that adds to the value of the coin via utility.

Additionally, the new crypto-as-a-service (CaaS) allows banks and brokerage firms to offer crypto services with BNB. These all serve as catalysts, as the coin serves as a link between the Web3 system and traditional finance.

The institutional adoption and regulatory stability that Binance has enjoyed have also contributed to the increasing investor confidence. Many are comfortable committing funds to Binance, and the ecosystem has maintained a regular quarterly burn of BNB to tighten the supply.

BNB could hit $1,500 and beyondWith limited supply, the price has continued to appreciate, and it looks likely to hit $1,500 next. As of press time, BNB traded at $1,308.33, which represented a 0.5% decline in the last 24 hours. The coin shed $24 as the broader crypto market fell by 2.08% within this time frame.

Despite a slight correction, market participants are still bullish, as seen with the trading volume, which has surged by 38.33% to $10.66 billion. The uptick suggests that investors are confident of further upside movement for Binance Coin.

Interestingly, in August 2025, Binance founder Changpeng Zhao and other analysts made projections that BNB could soar by 230% to take the price to $2,140. By their estimate, this should happen before the end of 2025.

With market participants anticipating $1,500 now, if the coin flips, $2,000 remains likely. 

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Ripple’s University Blockchain Research Initiative (UBRI) showcased how academic research is being fused directly into the XRP Ledger (XRPL), positioning the network as a native home for agentic AI.

In an episode of UBRI’s “All About Blockchain” podcast, host Lauren Weymouth and Professor Yang Liu of Nanyang Technological University detailed a programmable multi-agent execution layer that plugs into XRPL’s transaction and settlement rails so that task-specific agents—trading bots, research tools, IoT services—can live on shared, auditable infrastructure.

Ripple And NTU Build AI Layer For The XRP Ledger
RippleX teased the episode via X: “AI and blockchain are the future of secure, time-saving applications. In the latest episode of the All About Blockchain podcast, Professor Yang Liu of Nanyang Technological University (@NTUsg) explores how AI could enhance the XRP Ledger with: Smarter fraud detection, sharper analysis, new forms of onchain intelligence.”

AI and blockchain are the future of secure, time-saving applications.

In the latest episode of the All About Blockchain podcast, Professor Yang Liu of Nanyang Technological University (@NTUsg) explores how AI could enhance the XRP Ledger with:

➡️ Smarter fraud detection

➡️…

— RippleX (@RippleXDev) October 7, 2025

Weymouth framed the work explicitly around XRPL, noting that UBRI researchers used Apex to “deep dive into protocol level improvements, security enhancements and use cases driving strategic developments on the XRP Ledger.” She said Ripple’s own UBRI research search tool on xrpledgercommons.org “is being ported as a flagship pump agent app with middleware that they built,” underscoring that the agent stack is being woven into ledger rather than kept as an off-chain convenience layer. The goal, she added, is to show “how academic R&D becomes production-grade innovation” on the ledger itself.

Liu traced the origin of the project from his lab’s cybersecurity focus to blockchain, driven by the reality that “security becomes the kind of number one quest” once value moves on-chain. Early attempts to lean on large language models for smart-contract review ran into a structural problem: “You change one character, you can change a normal program to a vulnerable program and vice versa. But the language model is a probabilistic model. They cannot tell the tiny difference.” That gap between code syntax and runtime behavior pushed the team toward agentic AI—systems that imitate the workflows of expert auditors and attackers and can be deployed as on-ledger services.

“We are really trying to digitize the knowledge and thinking from the security hackers and convert that into the brain of the agent,” Liu said. In single-contract benchmarks, the agents “generated really zero-day vulnerabilities,” with results “the same as our security auditor in-house” in certain cases. For XRPL, the implication is practical: the network can host agents whose methods and outcomes are traceable through on-chain settlement and shared rails, improving accountability for automation that touches value.

Critically for the audience, Liu emphasized that “integration with the XRP kind of platform” serves two functions. First, it gives AI agents native access to payments and settlement. Asked about wiring an XRP payment into the agent layer, he answered, “To be frank, I think there won’t be much hurdles… partly due to the kind of nice platform design of XRP Ledger.”

Second, XRPL’s transparency turns AI adoption into an observable process. “Because the ledgers are on-chain… all the transactions are transparent. So, that can also improve the transparency of AI adoption,” he said. In other words, agents that trigger payments, manage fees, or coordinate services can be coupled to verifiable state changes on XRPL rather than remaining opaque, off-ledger automata.

What To Expect Next
Weymouth pressed on the production path for XRPL-facing software, and Liu’s answer returned to disciplined release cycles that matter on a live ledger: “well-defined… API and documentation, plus the kind of solid testing about this integration.” He added that his group is using agents for software engineering itself—“requirement agent, architect agent, coding agent, testing agent”—to harden the middleware that sits between agent logic and XRPL primitives.

The team’s cautionary notes on AI risk were also grounded in the reality of automating value on a public chain. Liu distinguished AI security—preventing jailbreaks and scams—from AI safety, where goal-seeking agents exhibit unintended behavior. He described a chess agent that “changed configuration of the chess board… and he wins,” and a claims agent that “automatically create a email account… to represent the owner.” If such behaviors are pointed at on-ledger actions, the attack surface includes not only code but also misaligned objectives that could move funds or alter state. “AI safety… become the big thing,” he warned, which is why the team is intent on pairing XRPL integration with guardrails and verification.

Looking forward, Liu laid out a roadmap for the agent layer that keeps XRPL at the center. Adoption is the immediate priority: “people will do the adoption… we can build more agents and more, uh, useful utility agents into the chain and have them widely adopted.” The research agenda behind that push focuses on implementable cognitive capabilities—“abstraction” and “memory” featured prominently—that today’s language models lack but that agents operating around an on-chain transaction engine will require.

“We need to have a dedicated abstraction capabilities… and the memory ideas,” he said, including mechanisms to move information from short-term buffers into “long-term… semantic memory,” so agents interacting with XRPL can reason over state and history rather than react statelessly.

Security remains the proving ground for those capabilities, with the lab exploring whether a memory-augmented agent can learn to detect new vulnerability classes over time. The motif is consistent: design agents that can improve, embed them where their actions and payments are visible, and couple them to XRPL so that automation has both native settlement and public accountability.

Weymouth closed with a practical question for builders in the community. Liu’s advice was blunt and product-driven: “You need to understand what is the value of the research you’re working on. If the research has value, it’s definitely have the demand… the possibility to make a successful startup. Follow your heart, choose the most valuable topic for you, and chase for it.”

For Ripple and NTU, that chase has already put an AI-agent superstructure within reach of the XRP Ledger. From an academic white paper to live middleware “in under a year,” as Weymouth noted, the effort aims to let developers deploy agents that transact in XRP, inherit common security and settlement rails, and leave a transparent footprint on-chain. Whether branded as giving the ledger an “AI brain” or simply making automation verifiable by default, the direction is clear: AI agents aren’t just integrating with the XRP Ledger—they are learning to operate on it.

At press time, XRP traded at $2.85.

XRP gets rejected at the 0.786 Fig again, 1-day chart | Source: XRPUSDT on TradingView.com
Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

After rebounding from its 200-day EMA band in early October, LTC price is showing signs of resurgence following a correction phase through Q3. With the probability of a Litecoin spot ETF approval rising, strengthening on-chain activity, and institutional enthusiasm building, the asset looks primed for a potential next leg upward.

Litecoin ETF Progress Sparks Renewed OptimismA major catalyst for the renewed excitement is the Litecoin ETF development. Canary recently filed an S-1 amendment for a spot Litecoin ETF with the ticker LTCC, marking a critical regulatory step toward potential approval. 

My take on the 95bp fee. It's pricey vs spot btc, but pretty normal to see higher fees for areas that are new to being ETF-ed and increasingly niche. That said, if there's flows other issuers will no doubt come and Terrordome that sht with cheaper products.

— Eric Balchunas (@EricBalchunas) October 7, 2025 According to Bloomberg analyst, such amendments often precede final decisions, suggesting that the ETF could soon enter its last stage of review.

However, the ongoing U.S. government shutdown has added an element of uncertainty, potentially delaying the Securities and Exchange Commission’s (SEC) response. 

Despite this, market confidence remains notably high. Data from Polymarket, a decentralized prediction platform, shows traders assigning a 96% probability that a Litecoin ETF will be approved before the end of 2025. 

This sentiment indicates growing institutional faith in the project’s regulatory prospects and long-term potential.

Technical Structure Strengthens Around Key LevelsFrom a technical perspective, the Litecoin price chart paints a tightening structure as LTC consolidates near the upper boundary of a symmetrical triangle pattern.

The LTC price today remains steady above $116, a key level that traders are closely watching for breakout confirmation.

The pattern indicates a compression phase that often precedes significant expansion. Analysts have outlined target levels at $140, $180, and $285 once a confirmed breakout materializes. 

Such a move could represent the start of a stronger bullish phase, particularly if volume surges alongside ETF progress.

#LTC Symmetrical Triangle Upper Border Test👀

Litecoin is testing the upper boundary of the triangle pattern with consolidation tightening on the weekly timeframe🧐

Target levels after breakout confirmation:
🎯 $140
🎯 $180
🎯 $285

Patience in consolidation creates power in… pic.twitter.com/6j6oDfNUzd

— Jonathan Carter (@JohncyCrypto) October 7, 2025 Historically, prolonged consolidation in Litecoin’s structure has often led to rapid directional moves. 

Hence, the current tightening could be seen as the calm before a larger expansion, aligning with the broader market’s anticipation of fresh catalysts.

The immediate focus remains on the LTC price USD range between $115 and $120. A decisive close above the upper resistance line could validate the breakout thesis and propel the asset toward its next targets. 

Conversely, if consolidation persists, accumulation may extend through mid-October before a more definitive move occurs.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Bitwise Chief Investment Officer Matt Hougan points to growing institutional concern over fiat currency debasement and robust inflows into Bitcoin ETFs as key drivers behind Bitcoin's surge to new all-time highs.

What Happened: In a CoinDesk interview on Tuesday, Hougan said he expects ETF inflows could reach $10–$20 billion in Q4 alone.

Hougan also reaffirmed his year-end target of $200,000 for Bitcoin (CRYPTO: BTC), contingent on continued ETF activity and adoption by corporate or government entities.

While Bitcoin remains a primary market driver, he noted that other assets, such as Ethereum (CRYPTO: ETH), Solana (CRYPTO: SOL), and XRP (CRYPTO: XRP) are gaining attention as the market narrative increasingly centers on stablecoin issuance and tokenization.

Solana's High Institutional Adoption

Hougan said that while Ethereum benefits from established market share and decentralization, Solana is gaining Wall Street's attention due to its speed and infrastructure tailored for institutional use.

He noted that even modest institutional interest in Solana could drive significant price appreciation.

The potential launch of Solana ETFs is expected to improve investor access and awareness, while the network's relatively small market capitalization compared to Bitcoin presents an opportunity for rapid gains.

Although early meme coin activity on Solana initially drew skepticism, Hougan argued it ultimately showcased the network's technical capabilities, signaling strong potential for institutional adoption.

Also Read: Bitcoin Could Reach $150,000 If Q4 Seasonality Delivers, Trader Says

Why It Matters: Hougan highlighted Bitwise's ongoing efforts to uplist its 10-crypto index fund into an ETF, noting that government shutdowns have slowed progress with the SEC.

While he remains optimistic about future approvals, he emphasized that regulatory uncertainty continues to constrain market growth and innovation.

Overall, Hougan painted a bullish outlook for crypto, particularly in stablecoins, tokenization, and DeFi, while stressing the importance of diversification and monitoring regulatory developments.

Read Next:

Bitcoin Holds Near $122,000 On Sentiment Shift, Ethereum, XRP, Dogecoin Slide
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Bitcoin and Ether ETFs Saw Big Inflows Tuesday as Investors Bought DipThe spot bitcoin funds drew in nearly $900 million, while the ether ETFs pulled more than $400 million. Oct 8, 2025, 2:46 p.m.

Bitcoin BTC$122,230.42 and ether ETH$4,447.06 prices dropped sharply on Tuesday, but that didn’t stop investors from pouring cash into crypto funds.

Spot bitcoin exchange-traded funds (ETFs) took in $876 million, according to data from Farside Investors. Combined with $1.2 billion in inflows on Monday as investors reacted to new record price over the weekend, the BTC funds have drawn in a fresh $2 billion in just the first two days of thew eek.

STORY CONTINUES BELOW

Ether ETFs, meanwhile, also saw a wave of demand, pulling in $420 million Tuesday, their strongest day of inflows this month. For the first two days of the week, the ETH funds have pulled in more than $600 million.

The wave of cash came as prices fell sharply, with bitcoin dropping 2.7% and ether by 5%.

More For You

Total Crypto Trading Volume Hits Yearly High of $9.72T

Sep 9, 2025

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025

What to know:

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025Gate exchange emerged as major player with 98.9% volume surge to $746 billion, overtaking Bitget to become fourth-largest platformOpen interest across centralized derivatives exchanges rose 4.92% to $187 billionView Full Report

More For You

Tom Lee's Bitmine Immersion Newest Target of Short-Seller Kerrisdale Capital

3 minutes ago

The company's model mimics a failing playbook and lacks transparency and leadership appeal, said Kerrisdale.

What to know:

Kerrisdale Capital announced a short position in ether treasury company BitMine Immersion (BMNR).The firm criticized BMNR’s “reflexive loop” strategy of issuing shares to buy ETH as outdated and unsustainable.Executive Chairman Tom Lee was singled out as lacking the influence needed to sustain investor enthusiasm.Read full story

Jupiter Exchange has announced the launch of JupUSD, its native Solana-based stablecoin developed in partnership with Ethena Labs. The stablecoin is built using Ethena's Stablecoin-as-a-Service stack and will integrate across the entire Jupiter ecosystem, including lending, trading, and perpetual markets.

Published
October 8, 2025 9:33am EDT

First 43 refreshed aircraft available by end of October with fixed recline design in economy class Canadian airline WestJet has introduced updated cabin interiors on select Boeing aircraft, adding three distinct seat classes and charging extra for seats that can recline.

The changes were announced by the airline on Sept. 23, and by the end of October, the first 43 refreshed Boeing 737-8 MAX and 737-800 will be available for passenger travel.

"The modern cabin experience will offer a bright, airy atmosphere with an upgraded design that features new seats, adjustable headrests and enhanced cushion and back support with a fixed recline design in Economy that helps preserve personal space," WestJet said in a press release.

Seat classes include premium, extended comfort and economy. Those wanting their seats to recline will need to book premium, and only 12 exist per plane. 

THESE ARE THE TOP GLOBAL AND US AIRLINES BASED ON NEW RANKINGS: 'LIKE FLYING PRIVATE'

Two WestJet Boeing 737 MAX 8 and Boeing 737-700, are pictured at Calgary International Airport in Alberta, Canada, on Aug. 6, 2025. (Artur Widak/NurPhoto / Getty Images)

WestJet explains the changes to passengers on its website, even stating that the back of the cabin rows 20–31 offer the least amount of space. 

SPIRIT AIRLINES FURLOUGHING 1,800 FLIGHT ATTENDANTS JUST BEFORE CHRISTMAS TRAVEL SEASON

A WestJet 737 airplane arrives at Toronto Pearson International Airport in Mississauga, Ontario, on Sept. 9, 2025. (Mike Campbell/NurPhoto / Getty Images)

"WestJet has always been a pioneer in making air travel available to Canadians, largely through keeping costs low to offer affordable airfare," Samantha Taylor, WestJet executive vice president and chief experience officer, said in a statement. 

WestJet's Boeing cabin reconfiguration now includes three seat classes on dozens of planes. (Westjet / Fox News)

CLICK HERE TO READ MORE ON FOX BUSINESS

"The layout for our refreshed cabin caters to our guests’ diverse preferences. Whether they opt for Premium seating with extra amenities and legroom or for more affordable ticket prices with less space, we’re excited to introduce this range of products for our guests to enjoy," she said. 

Key Takeaways Pfizer's deal with Trump cuts drug prices, boosts U.S. investment and lifts pharma sector sentiment.Investor optimism grows as major drugmakers eye similar tariff-free pricing agreements with Trump.J&J, Bayer and Novartis show strong growth momentum, making them attractive pharma investment picks.
Late last month, Pfizer (PFE - Free Report) announced a landmark deal with the Trump administration to cut drug prices and expand U.S. innovation and manufacturing.

Under the deal, Pfizer agreed to slash prices of some of its drugs to align their cost with those in comparable developed countries, supporting President Trump’s Most Favored Nation (MFN) pricing proposal. The company will also offer significant discounts on key treatments through the new direct purchasing platform, TrumpRx.gov.

In exchange, Pfizer will receive a three-year exemption from tariffs on pharmaceutical imports if it increases U.S. manufacturing investment. To that end, Pfizer has committed an additional $70 billion over the coming years to strengthen its U.S. research and production footprint.

Pfizer’s drug-pricing deal with Trump seems to have alleviated the two biggest concerns surrounding the drug and biotech industry this year – tariff and MFN pricing.

The goal of Trump’s proposed MFN pricing policy is to ensure that U.S. consumers pay the same price for some prescription drugs as in some comparably developed nations. It is feared that such a policy, if implemented, can hurt prices and reimbursement of prescription drugs.

As regards tariff, President Trump had threatened to impose heavy tariffs, as high as 250%, on pharmaceutical imports. Trump’s repeated threats to impose tariffs on pharmaceutical imports were aimed at pushing American pharma companies to shift pharmaceutical production back to the United States, primarily from European and Asian countries.

The PFE-Trump deal set off a surge in stocks of large drug stocks like Merck (MRK - Free Report) , AstraZeneca, AbbVie and Eli Lilly, among others, as these drugmakers could be the next in line to sign similar deals with the Trump administration. Many of the large drugmakers have already committed to investing billions to boost domestic investments.

The deal, along with a recent surge in M&A activity, has improved investor outlook toward the pharma sector, which has struggled this year due to tariff and pricing fears and broader macro headwinds. The deal between Pfizer and Trump has raised hopes of a sustainable sector recovery, as Trump offers to hold off the tariffs on pharmaceutical imports to sign similar deals with other drugmakers

The SPDR S&P Biotech exchange-traded fund (XBI) is up 9.2% in a month and 15.1% YTD. The Large Cap Pharma sector has risen 8.4% in a month and 8.1% YTD.

Image Source: Zacks Investment Research

With the drug/biotech industry riding high, we discuss three large drugmakers, J&J (JNJ - Free Report) , Bayer (BAYRY - Free Report) and Novartis (NVS - Free Report) , which can prove to be great inclusions in your portfolio. These companies have seen their stock prices rise this year, as seen in the chart below.

Image Source: Zacks Investment Research

Bayer’s Pharmaceuticals Unit Driving GrowthBayer’s key drugs, Nubeqa for cancer and Kerendia for chronic kidney disease associated with type II diabetes, are fueling growth in its Pharmaceuticals division, making up for the decline in sales of oral anticoagulant Xarelto. Bayer is also working to expand the labels of Nubeqa and Kerendia, which, if successful, can further drive growth.

The company also plans to launch two new drugs in 2025 — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a specific form of heart disease.

The Crop Science business also posted an increase in sales in the second quarter after being under pressure over the past few quarters. The Consumer Health segment was  soft in the first half of 2025.

This Zacks Rank #1 (Strong Buy) company’s shares have risen 65.5% so far this year. You can see the complete list of today’s Zacks #1 Rank stocks here.

Estimates for its 2025 earnings per share have increased from $1.28 to $1.33 over the past 90 days, while those for 2026 have increased from $1.35 per share to $1.38 per share. 

J&J’s Innovative Medicine Unit Strong, MedTech ImprovingJ&J’s Innovative Medicine unit, which makes drugs, is showing a growth trend, despite the loss of exclusivity (LOE) of blockbuster drug, Stelara, and the negative impact of the Part D redesign. J&J expects continued growth in the second half of 2025 to be driven by its key products such as Darzalex, Tremfya, Spravato and Erleada, as well as new drugs like Carvykti, Tecvayli and Talvey and new indications for Tremfya and Rybrevant. J&J’s MedTech segment sales improved in the second quarter from the first-quarter levels, driven by Cardiovascular, Surgery and Vision, which are likely to drive growth in the second half too.

J&J is also rapidly advancing its pipeline, attaining significant clinical and regulatory milestones that will help accelerate growth through the back half of the decade. J&J has also been on an acquisition spree, with the latest acquisition of Intra-Cellular Therapies strengthening its presence in the neurological and psychiatric drug market.

J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first.

J&J has a Zacks Rank #2 (Buy).

The stock has risen 30.6% year to date. The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 per share, while that for 2026 has risen from $11.00 per share to $11.37 per share over the past 90 days.

Key Drugs Boost Novartis’ Top-Line GrowthWith the separation of Sandoz, Novartis has become a pure-play pharmaceutical company.  Its performance has been good in the last few quarters. Novartis maintains strong momentum on the back of a strong and diverse portfolio with drugs like Kisqali, Kesimpta, Pluvicto and Leqvio. The uptake of Pluvicto and Scemblix has been outstanding and should propel top-line growth. Approval of new drugs and label expansion of existing drugs should enable Novartis to offset the adverse impacts of the generic competition of key drugs.

Novartis is also looking to solidify its presence in the promising gene therapy space. The recent spate of acquisitions and collaborations has strengthened its pipeline. However, generic erosion of some drugs and recent pipeline setbacks are a concern. One of its top drugs, Entresto, is likely to lose patent protection. 

Novartis has a Zacks Rank #3 (Hold) at present. The Zacks Consensus Estimate for this Swiss drugmaker’s 2025 EPS has increased from $8.92 to $9.03 over the past 90 days, while that for 2026 has risen from $9.27 to $9.41 during the same timeframe. The stock has risen 35.2% so far this year.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Photo by Smith Collection/Gado/Getty Images

Getty Images

Oracle (ORCL) stock could be an excellent option to capitalize on the momentum. Why? This is due to its strong margins, low-debt capital structure, fair valuation, and positive momentum. Here is some data.

Revenue Growth: Oracle experienced revenue growth of 9.7% LTM and an average of 10.2% over the last 3 years.Long-Term Profitability: Approximately 35.6% operating cash flow margin and an average operating margin of 30.3% over the last 3 years.Strong Momentum: Currently in the top 10 percentile of stocks in terms of “trend strength” – our exclusive momentum metric.Room To Run: Despite its current momentum, ORCL stock is trading 13% lower than its 52-week peak.While revenue growth is beneficial, this choice centers on maintaining momentum with quality — which we assess through margins (indicative of pricing power / a robust business model) and capital structure (not overly laden with debt).

For a brief overview, Oracle offers cloud software as a service, industry-specific cloud solutions, application licenses, license support, an enterprise database, a development language, and middleware services.

Comparison of ORCL with S&P500 Median

Trefis

However, do these figures convey the entire picture? Read Buy or Sell ORCL Stock to determine if Oracle still possesses an advantage that can withstand scrutiny.

This is one perspective on stocks. Trefis High Quality Portfolio assesses far more factors and aims to mitigate stock-specific risks while providing upside potential.

Stocks Like These Can Outperform. Here Is DataHere is how we conduct our selection: We evaluate stocks with > $2 Bil in market capitalization, high operating and CFO (cash flow from operations) margins, no incidents of more than 15% revenue decline in the past 5 years, reasonable valuation, a low-debt capital structure, and strong momentum as defined by our proprietary momentum metric.

Below are statistics for stocks using this selection strategy from 12/31/2016 to 6/30/2025.

Average 12-month forward returns of nearly 15%12-month win rate (percentage of selections returning positive) of approximately 60%But Consider The RiskThat being said, Oracle is not exempt from large declines. It fell nearly 77% during the Dot-Com Bubble and dropped over 41% during the Global Financial Crisis. The Inflation Shock was also harsh, with a 40% decline. Even smaller events — such as the 2018 Correction and Covid Pandemic — caused it to decrease around 19% and 29% respectively. Strong fundamentals are important, but during sell-offs, Oracle can experience significant pullbacks.

The Trefis High Quality (HQ) Portfolio, composed of 30 stocks, has a history of consistently outperforming its benchmark, which includes all 3 - the S&P 500, S&P mid-cap, and Russell 2000 indices. What is the reason for this? Collectively, HQ Portfolio stocks have generated better returns with lower risk compared to the benchmark index; providing a more stable investment experience, as highlighted by HQ Portfolio performance metrics.

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.

We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.

Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.

The Zacks Earnings ESP, ExplainedThe Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.

Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.

Should You Consider Exact Sciences?Now that we understand what the ESP is and how beneficial it can be, let's dive into a stock that currently fits the bill. Exact Sciences (EXAS - Free Report) earns a #1 (Strong Buy) right now and its Most Accurate Estimate sits at $0.13 a share, just 27 days from its upcoming earnings release on November 4, 2025.

EXAS has an Earnings ESP figure of +32.65%, which, as explained above, is calculated by taking the percentage difference between the $0.13 Most Accurate Estimate and the Zacks Consensus Estimate of $0.1. Exact Sciences is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

EXAS is just one of a large group of Medical stocks with a positive ESP figure. Incyte (INCY - Free Report) is another qualifying stock you may want to consider.

Incyte, which is readying to report earnings on November 4, 2025, sits at a Zacks Rank #2 (Buy) right now. Its Most Accurate Estimate is currently $1.85 a share, and INCY is 27 days out from its next earnings report.

The Zacks Consensus Estimate for Incyte is $1.65, and when you take the percentage difference between that number and its Most Accurate Estimate, you get the Earnings ESP figure of +11.90%.

EXAS and INCY's positive ESP metrics may signal that a positive earnings surprise for both stocks is on the horizon.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.

The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.

The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.

The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP is more formally known as the Expected Surprise Prediction, and it aims to grab the inside track on the latest analyst estimate revisions ahead of a company's report. The idea is relatively intuitive as a newer projection might be based on more complete information.

The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction. The Zacks Rank is also factored into the ESP metric to better help find companies that appear poised to top their next bottom-line consensus estimate, which will hopefully help lift the stock price.

In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.

Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.

Should You Consider Hershey?Now that we understand what the ESP is and how beneficial it can be, let's dive into a stock that currently fits the bill. Hershey (HSY - Free Report) earns a #3 (Hold) right now and its Most Accurate Estimate sits at $1.08 a share, just 22 days from its upcoming earnings release on October 30, 2025.

HSY has an Earnings ESP figure of +1.61%, which, as explained above, is calculated by taking the percentage difference between the $1.08 Most Accurate Estimate and the Zacks Consensus Estimate of $1.06. Hershey is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

HSY is just one of a large group of Consumer Staples stocks with a positive ESP figure. Monster Beverage (MNST - Free Report) is another qualifying stock you may want to consider.

Monster Beverage is a Zacks Rank #3 (Hold) stock, and is getting ready to report earnings on November 6, 2025. MNST's Most Accurate Estimate sits at $0.49 a share 29 days from its next earnings release.

Monster Beverage's Earnings ESP figure currently stands at +2.09% after taking the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $0.48.

HSY and MNST's positive ESP metrics may signal that a positive earnings surprise for both stocks is on the horizon.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.

We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.

Now that we know how important earnings and earnings surprises are, it's time to show investors how to take advantage of these events to boost their returns by utilizing the Zacks Earnings ESP filter.

The Zacks Earnings ESP, ExplainedThe Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

When we join a positive earnings ESP with a Zacks Rank #3 (Hold) or stronger, stocks posted a positive bottom-line surprise 70% of the time. Plus, this system saw investors produce roughly 28% annual returns on average, according to our 10 year backtest.

Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.

Should You Consider Marathon Petroleum?Now that we understand what the ESP is and how beneficial it can be, let's dive into a stock that currently fits the bill. Marathon Petroleum (MPC - Free Report) earns a #3 (Hold) right now and its Most Accurate Estimate sits at $2.97 a share, just 27 days from its upcoming earnings release on November 4, 2025.

By taking the percentage difference between the $2.97 Most Accurate Estimate and the $2.94 Zacks Consensus Estimate, Marathon Petroleum has an Earnings ESP of +1.04%. Investors should also know that MPC is one of a large group of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

MPC is just one of a large group of Oils and Energy stocks with a positive ESP figure. Western Midstream (WES - Free Report) is another qualifying stock you may want to consider.

Slated to report earnings on November 5, 2025, Western Midstream holds a #3 (Hold) ranking on the Zacks Rank, and its Most Accurate Estimate is $0.94 a share 28 days from its next quarterly update.

The Zacks Consensus Estimate for Western Midstream is $0.87, and when you take the percentage difference between that number and its Most Accurate Estimate, you get the Earnings ESP figure of +8.05%.

MPC and WES' positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Wall Street watches a company's quarterly report closely to understand as much as possible about its recent performance and what to expect going forward. Of course, one figure often stands out among the rest: earnings.

The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.

The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.

The Zacks Earnings ESP, ExplainedThe Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate (being the most recent) against the overall Zacks Consensus Estimate. The percentage difference provides the ESP figure. The system also utilizes our core Zacks Rank to provide a stronger system for identifying stocks that might beat their next quarterly earnings estimate and possibly see the stock price climb.

Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.

Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.

Should You Consider Ralph Lauren?Now that we understand what the ESP is and how beneficial it can be, let's dive into a stock that currently fits the bill. Ralph Lauren (RL - Free Report) earns a #2 (Buy) right now and its Most Accurate Estimate sits at $3.51 a share, just 29 days from its upcoming earnings release on November 6, 2025.

RL has an Earnings ESP figure of +4.99%, which, as explained above, is calculated by taking the percentage difference between the $3.51 Most Accurate Estimate and the Zacks Consensus Estimate of $3.34. Ralph Lauren is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

RL is part of a big group of Consumer Discretionary stocks that boast a positive ESP, and investors may want to take a look at Carnival (CCL - Free Report) as well.

Carnival, which is readying to report earnings on December 19, 2025, sits at a Zacks Rank #1 (Strong Buy) right now. Its Most Accurate Estimate is currently $0.25 a share, and CCL is 72 days out from its next earnings report.

For Carnival, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $0.23 is +7.13%.

RL and CCL's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure helps cut through all the noise.

We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.

The ability to identify stocks that are likely to top quarterly earnings expectations can be profitable, but it's no simple task. Here at Zacks, our Earnings ESP filter helps make things easier.

The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP is more formally known as the Expected Surprise Prediction, and it aims to grab the inside track on the latest analyst estimate revisions ahead of a company's report. The idea is relatively intuitive as a newer projection might be based on more complete information.

The core of the ESP model is comparing the Most Accurate Estimate to the Zacks Consensus Estimate, where the resulting percentage difference between the two equals the Expected Surprise Prediction. The Zacks Rank is also factored into the ESP metric to better help find companies that appear poised to top their next bottom-line consensus estimate, which will hopefully help lift the stock price.

Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.

Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.

Should You Consider Goldman Sachs?Now that we understand what the ESP is and how beneficial it can be, let's dive into a stock that currently fits the bill. Goldman Sachs (GS - Free Report) earns a #3 (Hold) right now and its Most Accurate Estimate sits at $11.11 a share, just six days from its upcoming earnings release on October 14, 2025.

GS has an Earnings ESP figure of +1.68%, which, as explained above, is calculated by taking the percentage difference between the $11.11 Most Accurate Estimate and the Zacks Consensus Estimate of $10.93. Goldman Sachs is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

GS is one of just a large database of Finance stocks with positive ESPs. Another solid-looking stock is Wells Fargo (WFC - Free Report) .

Slated to report earnings on October 14, 2025, Wells Fargo holds a #3 (Hold) ranking on the Zacks Rank, and its Most Accurate Estimate is $1.56 a share six days from its next quarterly update.

For Wells Fargo, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $1.54 is +1.02%.

GS and WFC's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Key Takeaways Pfizer's oncology revenues grew 9% in H125 and now comprise more than 25% of total company sales.Q3 results hinge on Xtandi, Lorbrena and Braftovi-Mektovi offsetting Ibrance's weaker performance.Oncology biosimilars and Seagen's ADCs, including Padcev, remain pivotal growth drivers for Pfizer.
Pfizer (PFE - Free Report) is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. 

The addition of Seagen in 2023 strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer’s revenues in the first half of 2025.

Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025. Investors will be keen to know how its oncology segment performed in the third quarter when the company announces results on Nov. 4.

Pfizer’s oncology sales in the third quarter are expected to have been driven by higher sales of key drugs like Xtandi, Lorbrena and the Braftovi-Mektovi combination, which should make up for declining sales of drugs like Ibrance.

Sales of Ibrance are likely to have declined due to continued competitive pressure across markets, generic entry in select international markets, and the impact of Medicare Part D redesign in the United States. Medicare Part D redesign is expected to have had a negative impact on sales of some other oncology drugs like Xtandi and Lorbrena.

Among the ADCs added from the 2023 acquisition of Seagen, while strong demand trends are likely to have pulled up sales of Padcev, competitive pressure in the United States is expected to have hurt sales of Adcetris. A one-time benefit from a transition to a wholesale distribution model for Seagen products pulled up Padcev’s sales in the second quarter, which will be absent in the third quarter.

Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Revenues from oncology biosimilars are likely to have risen in the third quarter.

Pfizer should also provide updates on its oncology candidates in late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin on the third-quarter conference call.

Competition in the Oncology SpaceOther large players in the oncology space are AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .

For AstraZeneca, oncology sales now comprise around 43% of total revenues. Sales in its oncology segment rose 16% in the first half of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).

Merck’s key oncology medicines are PD-L1 inhibitor Keytruda and PARP inhibitor Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck’s pharmaceutical sales. Keytruda’s sales rose 6.6% to $15.1 billion in the first half of 2025.

Bristol-Myers’ key cancer drug is PD-L1 inhibitor, Opdivo, which accounts for around 20% of its total revenues. Opdivo’s sales rose 9% to $4.82 billion in the first half of 2025.

PFE’s Price Performance, Valuation and EstimatesPfizer’s stock has declined 1.0% so far this year against an increase of 8.0% for the industry. 

Image Source: Zacks Investment Research

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.45 forward earnings, lower than 15.89 for the industry and the stock’s 5-year mean of 10.62.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2025 earnings has risen from $3.11 per share to $3.12 per share, while that for 2026 has gone up from $3.09 to $3.10 per share over the past 60 days.

Image Source: Zacks Investment Research

Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Investors in Ameren Corporation (AEE - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 17, 2025 $50.00 Put had some of the highest implied volatility of all equity options today.

What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?Clearly, options traders are pricing in a big move for Ameren shares, but what is the fundamental picture for the company? Currently, Ameren is a Zacks Rank #3 (Hold) in the Utility - Electric Power industry that ranks in the Top 31% of our Zacks Industry Rank. Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from earnings of $1.75 per share to $1.83 in that period.

Given the way analysts feel about Ameren right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options?Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.

Click to see the trades now >>

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

CALGARY, Alberta--(BUSINESS WIRE)--Pembina Pipeline Corporation ("Pembina" or the "Company") (TSX: PPL; NYSE: PBA) announced today that it is considering an offering of subordinated notes under its short form base shelf prospectus dated December 13, 2023.

If a successful offering is completed, the Company intends to use the net proceeds of the offering to redeem its outstanding Cumulative Redeemable Rate Reset Class A Preferred Shares, Series 9 (TSX: PPL.PR.I) and for general corporate purposes. There is no certainty that Pembina will ultimately complete the offering being considered or as to the terms or timing on which such an offering might be completed.

This news release does not constitute an offer to sell or the solicitation of an offer to buy subordinated notes in any jurisdiction. The subordinated notes considered to be offered have not been approved or disapproved by any regulatory authority. The subordinated notes have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities law, and may not be offered or sold within the United States or to, or for the account or benefit of, United States persons.

About Pembina

Pembina Pipeline Corporation is a leading energy transportation and midstream service provider that has served North America's energy industry for more than 70 years. Pembina owns an extensive network of strategically located assets, including hydrocarbon liquids and natural gas pipelines, gas gathering and processing facilities, oil and natural gas liquids infrastructure and logistics services, and an export terminals business. Through our integrated value chain, we seek to provide safe and reliable energy solutions that connect producers and consumers across the world, support a more sustainable future and benefit our customers, investors, employees and communities. For more information, please visit www.pembina.com.

Purpose of Pembina: We deliver extraordinary energy solutions so the world can thrive.

Pembina is structured into three Divisions: Pipelines Division, Facilities Division and Marketing & New Ventures Division.

Pembina's common shares trade on the Toronto and New York stock exchanges under PPL and PBA, respectively. For more information, visit www.pembina.com.

Forward-Looking Information and Statements

This news release contains certain forward-looking statements and forward-looking information (collectively, "forward-looking statements"), including forward-looking statements within the meaning of the "safe harbor" provisions of applicable securities legislation that are based on Pembina's current expectations, estimates, projections and assumptions in light of its experience and its perception of historical trends. In some cases, forward-looking statements can be identified by terminology such as "expect", "intend", "will", "shall", and similar expressions suggesting future events or future performance.

In particular, this news release contains forward-looking statements relating to: the offering of subordinated notes and the use of the net proceeds from any successful offering of subordinated notes. These forward-looking statements are based on certain assumptions that Pembina has made in respect thereof as at the date of this news release, including: oil and gas industry exploration and development activity levels and the geographic region of such activity; that favourable market conditions exist; the success of Pembina's operations; prevailing commodity prices, interest rates, carbon prices, tax rates and exchange rates; the ability of Pembina to maintain current credit ratings; the availability of capital to fund future capital requirements relating to existing assets and projects; future operating costs; geotechnical and integrity costs; that all required regulatory and environmental approvals can be obtained on the necessary terms in a timely manner; prevailing regulatory, tax and environmental laws and regulations; maintenance of operating margins; and certain other assumptions in respect of Pembina's forward-looking statements detailed in Pembina's Annual Information Form for the year ended December 31, 2024 (the "AIF") and Management's Discussion and Analysis for the year ended December 31, 2024 (the "Annual MD&A"), which were each filed on SEDAR+ on February 27, 2025, in Pembina's Management's Discussion and Analysis for the three and six months ended June 30, 2025 (the "Interim MD&A"), which was filed on SEDAR+ on August 7, 2025, and from time to time in Pembina's public disclosure documents available at www.sedarplus.ca, www.sec.gov and through Pembina's website at www.pembina.com.

These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties, including, but not limited to: the regulatory environment and decisions and Indigenous and landowner consultation requirements; the impact of competitive entities and pricing; reliance on third parties to successfully operate and maintain certain assets; the strength and operations of the oil and natural gas production industry and related commodity prices; non-performance or default by counterparties to agreements with Pembina or one or more of its affiliates; actions taken by governmental or regulatory authorities; the ability of Pembina to acquire or develop the necessary infrastructure in respect of future development projects; fluctuations in operating results; adverse general economic and market conditions in Canada, North America and worldwide; the ability to access various sources of debt and equity capital; changes in credit ratings; counterparty credit risk; and certain other risks and uncertainties detailed in the AIF, Annual MD&A, Interim MD&A and from time to time in Pembina's public disclosure documents available at www.sedarplus.ca, www.sec.gov and through Pembina's website at www.pembina.com.

Accordingly, readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. The forward-looking statements contained in this news release are expressly qualified by the above statements. Pembina does not undertake any obligation to publicly update or revise any forward-looking statements or information contained herein, except as required by applicable laws.